Category Archives: lentivirus

Publication-Lentivirus

Selected Publications using Genemed’s Lentivirus Products/Services Publications Link to the article Products/Services J. Nan et.al, ‘Tnfr2 Stimulation Promotes Mitochondrial Fusion Via Stat3- and Nf-Kb-Dependent Activation of Opa1 Expression’, Circ Res, 121 (2017), 392-410. http://www.ncbi.nlm.nih.gov/pubmed/28637784 Lentivirus J. Wu et.al, ‘Microrna-30 Family Members Regulate Calcium/Calcineurin Signaling in Podocytes’, J Clin Invest, 125 (2015), 4091-106. http://www.ncbi.nlm.nih.gov/pubmed/26436650 Lentivirus H. […]

Promise-ORF™viral CDNA library: Sequence-verified ORF/CDNA clones in lentivirus (lentiviral ORF clones), AAV, adenovirus and mammalian expression vectors

Promise-ORF™ GeneMedi’s Promise-ORF™ offers the larger collection of ORF/cDNA expression clones of human, mouse, rat and some other species. All ORFs expression clones in viral vectors (lentivirus, AAV and adenovirus) or mammalian expression vectors are sequences-verified. Using our Promise-ORF™ viral-ready expression vectors, you can easily promote your viral vectors packaging, or you can transfect your mammalian […]

Viral vector-based vaccines: Lentiviral vector-based vaccines

COVID-19 vaccine development protocol: PSV Based Neutralization Assay Lentivirus (lente-, Latin for “slow”) is a genus of retroviruses, medium sized (80-100nm) and enveloped, slightly pleomorphic, spherical with an isometric nucleocapsid containing two copies of positive-sense ssRNA genome (Fig. 11A). Most lentiviral vectors are based on the Human Immunodeficiency Virus (HIV), which causes AIDS, a chronic […]

Lentivirus Infection Protocol for stable cell line development (CLD)

Lentivirus Protocol Download This protocol is for the stable cell line construction based on puromycin selection. Day 1: Seed target cells in 24-well plates. The number of seeding cells differs according to the cell proliferation rate.Day 2: Target cells should be approximately 50%-70% confluent. For polybrene accessible cells, mix the culture medium with proper concentrations of polybrene. […]

Recombinant Lentivirus System

Lentivirus Protocol Download a) Introduction of recombinant lentivirus vector system Since wild-type HIV-1 based lentivirus is associated with destruction of host immune system, especially CD4+ helper T lymphocytes, multiple generations of lentivirus vectors have been designed with enhanced safety features and as attractive vectors for gene therapy. To date, there have been three generations of […]

Life Cycle of Lentivirus

Lentivirus Protocol Download The life cycle of HIV-1 starts with viral entry, in which process the virus binds to the CD4 receptor or a coreceptor (CCR5 or CXCR4) with gp120 protein, thereby anchoring itself onto host cell surface, allowing fusion between the cellular and viral membranes. After entry into the cell, the viral nucleoprotein together […]

Lentivirus Genome Structure and Virus Assembly

Lentivirus Protocol Download Lentivirus, as represented by HIV-1, is a medium-sized (80-100nm) and enveloped, slightly pleomorphic, spherical virus with an isometric nucleocapsid (Figure1A). Unlike other retroviruses, HIV-1 is featured by a set of additional regulatory and accessory genes [11,12]. Its DNA genome, transcribed from HIV-1 ssRNA, is approximately 9.7 kb and contains 9 ORFs. Besides […]

Advantages and Drawbacks of Lentivirus Vector-mediated Gene Delivery

Lentivirus Protocol Download a) Advantages of lentivirus -mediated gene delivery Lentivirus has been developed as an attractive candidate for creating viral vectors for gene therapy due to various advantages.1) Customized cloning for any other gene ORF expression, shRNA/miRNA and CRISPR/Cas9.2) No known immunogenic proteins generated.3) High titer. 108TU/ml or 109TU/ml lentiviral titer for cell line […]

Lentivirus Gene Therapy

Lentivirus Protocol Download Lentivirus has been proved as an excellent gene therapy vector. To date, more than 236 clinical trials have been carried out using lentivirus vectors for gene delivery [4], and promising gene therapy outcomes from recombinant lentivirus have been achieved from clinical trials for a great number of diseases (Table 1), especially for […]